## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.12 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.3% MRS), overbought RSI (73).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($199.67)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 1)

**1. Johnson & Johnson MedTech to shift to business unit-led structure in 2026**
- Source: MassDevice | 20251203T183654 | Somewhat-Bullish | Relevance: 100%
- Johnson & Johnson MedTech is enacting an organizational restructuring set to begin in January 2026, shifting from a regional operating model to a business unit-led structure globally. This change, building on earlier decentralization efforts and coinciding with the separation of DePuy Synthes Orthopaedics, aims to enhance accountability, streamline decision-making, and increase competitiveness for its various units. The restructuring will give each business unit full accountability for performance, from strategy to execution, across the globe, though customer-facing roles and some existing units will not be affected.

**2. Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook**
- Source: ts2.tech | 20251202T174646 | Bullish | Relevance: 100%
- Johnson & Johnson (JNJ) is trading near all-time highs due to a strong 2025 rally, a new EU drug approval for IMAAVY, a $3.05 billion oncology acquisition, and the planned spin-off of its orthopaedics business. The article details JNJ's recent financial performance, pipeline developments, valuation perspectives, and ongoing legal risks, providing an outlook for 2026.

**3. J&J gets EU approval for Imaavy in gMG**
- Source: pharmaphorum | 20251202T133323 | Bullish | Relevance: 100%
- Johnson & Johnson's Imaavy (nipocalimab) has received EU approval for treating generalized myasthenia gravis (gMG) in both adolescent and adult patients, making it the first FcRn blocker cleared for adolescents in Europe. This approval is based on positive results from the phase 3 Vivacity-MG3 and phase 2/3 Vibrance-MG studies, positioning Imaavy to compete with existing treatments from Argenx and UCB, while also having received approval in the US, Brazil, and Japan. J&J acquired nipocalimab through its 2020 acquisition of Momenta Pharmaceuticals, and the drug is being explored for multiple other autoimmune conditions with a projected annual sales potential of $5 billion.

**4. Johnson & Johnson Director John G Morikis Acquires 1,250 Shares**
- Source: TradingView | 20251201T235122 | Somewhat-Bullish | Relevance: 100%
- John G Morikis, a director and 10% owner of Johnson & Johnson, purchased 1,250 shares of the company's common stock. The transaction, totaling $257,687, occurred on November 26, 2025, with shares priced at $206.15 each. Following this purchase, Morikis now directly owns 1,848 shares of Johnson & Johnson.

**5. Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength â€“ December 1, 2025**
- Source: ts2.tech | 20251201T160623 | Somewhat-Bullish | Relevance: 100%
- Johnson & Johnson (JNJ) stock is trading near record highs in December 2025, driven by strong performance, EU approval for its novel gMG drug IMAAVY (nipocalimab), and strategic acquisitions like Halda Therapeutics for $3.05 billion. The company reported solid Q3 2025 earnings and raised full-year guidance, reinforcing its status as a Dividend Aristocrat with a reliable, growing dividend. Despite strong fundamentals and positive sentiment, most analyst price targets suggest limited near-term upside after a ~47% YTD rally, and talc litigation remains a significant risk factor.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Barclays | $197 | $176 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Forward P/E 17.8x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (1 raises, avg +12%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $500.2B |
| Beta | 0.35 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 17.8 |
| Current P/E | 18.9 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.0% to 1.7% (-4.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.3pp (needs >4.0% for momentum thesis). MRS_5 (-0.8%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.6% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 73, risk of mean reversion. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.67% (CS: 69) | Neutral |
| RSI_14 | 73.2 | Overbought |
| MACD Histogram | 0.27 | Bullish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.209x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $205.33
- **Stop Loss:** $199.67 (2.8% risk)
- **Target:** $216.65 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 167
- **Position Value:** $34,290.11
- **Portfolio %:** 34.29%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*